Document Detail


A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
MedLine Citation:
PMID:  8037889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Vigabatrin was designed to increase the levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. It does this by replacing GABA as a substrate for the action of the catabolic enzyme GABA-transaminase. As a result of this inhibition, neuronal GABA levels are elevated, resulting in enhanced endogenous GABA transmission. A number of clinical trials assessing the effect of vigabatrin in epilepsy have been completed. Vigabatrin is of proven benefit in partial seizures and secondarily generalised tonic clonic seizures, and it is licensed for use as adjunctive therapy in these conditions in several European countries. It has been shown to be effective in some epilepsy syndromes in children including West's syndrome, infantile spasms and cryptogenic partial seizures. Its effect on primary generalised tonic clonic seizures is variable, while there is considerable evidence that it has a deleterious effect on myoclonic and absence seizures. There have been a few reports of the benefits of vigabatrin in other neurological disorders including tardive dyskinesia, degenerative ataxias and GABA metabolism disorders. The adverse effects associated with vigabatrin are similar to those seen with other anticonvulsants, with a predominance of CNS effects including somnolence, fatigue, irritability, dizziness and headache. Psychiatric symptoms including depression and psychosis are seen in a small number of patients and cause the most problems. These often necessitate discontinuation of vigabatrin, which usually results in resolution of symptoms.
Authors:
J Srinivasan; A Richens
Related Documents :
18772699 - What's in the literature?
22080789 - The clock gene and mood disorders: a case-control study and meta-analysis.
21835699 - Mycobacterium tuberculosis beijing genotype: a template for success.
3950099 - Development of proliferating trichilemmal cyst in organoid nevus. presentation of two c...
1396539 - Single photon emission computed tomography using perfusion tracers in seizure disorders.
9530949 - An aggressive seizure and behavioural disorder following trivial head injury.
6887099 - Fatal but clinically undiagnosed tuberculosis.
6984349 - Vestibular implications of noise-induced hearing loss.
23827859 - Xpert(®) mtb/rif in pleural fluid for the diagnosis of tuberculosis [short communicati...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  10     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  1994 May 
Date Detail:
Created Date:  1994-08-25     Completed Date:  1994-08-25     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  395-405     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
4-Aminobutyrate Transaminase / antagonists & inhibitors
Animals
Anticonvulsants / adverse effects*,  therapeutic use*
Brain / drug effects,  metabolism
Child
Clinical Trials as Topic
Double-Blind Method
Epilepsy / drug therapy
Humans
Nervous System Diseases / drug therapy*
Risk Factors
Single-Blind Method
Vigabatrin
gamma-Aminobutyric Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticonvulsants; 56-12-2/gamma-Aminobutyric Acid; EC 2.6.1.19/4-Aminobutyrate Transaminase; GR120KRT6K/Vigabatrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinically significant drug interactions with the oral anticoagulants.
Next Document:  Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio.